CBM stock forecast
Our latest prediction for Cambrex Corp.'s stock price was made on the Sept. 4, 2018 when the stock price was at 67.00$.
In the short term (2weeks), CBM's stock price should underperform the market by -0.46%. During that period the price should oscillate between -5.02% and +3.96%.
In the medium term (3months), CBM's stock price should underperform the market by -2.01%. During that period the price should oscillate between -12.76% and +12.09%.Get email alerts
About Cambrex Corp.
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.
At the moment the company generates 580M USD in revenues.
On its last earning announcement, the company reported a profit of 3.91$ per share.
The book value per share is 18.73$
Three months stock forecastSept. 4, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|